Stets R, et al. - Researchers assessed 386 cases in the omadacycline group and 388 patients in the moxifloxacin group to study comparatively the impact of omadacycline in community-acquired bacterial pneumonia. They found omadacycline noninferior to moxifloxacin for early clinical response. They noticed adverse events emerged after treatment initiation in 41.1% of the candidates in the omadacycline group whereas in 48.5% of subjects in the moxifloxacin group. Twelve deaths ie, 8 in the omadacycline group and 4 in the moxifloxacin group were also reported.